OSTX (STOCKS)
OS Therapies Incorporated
$1.330000
+0.030000 (+2.31%)
Prev close: $1.300000
Company Information
- Exchange
- XASE
- Sector
- Health Technology
- Industry
- Biotechnology
- CEO
- Paul A. Romness
- Asset Type
- stocks
- Website
- Visit
Fundamentals
- Market Cap
- $55.91M
- Employees
- 5
- P/E (TTM)
- -1.40
- P/B (TTM)
- -8.04
- Dividend Yield
- —
Technical Indicators
- SMA 10
- —
- SMA 20
- —
- SMA 50
- —
- EMA 9
- —
- EMA 21
- —
- RSI
- —
- MACD State
- —
Analyst Recommendations
2
Strong Buy
7
Buy
1
Hold
0
Sell
Recent News
No recent news found for this ticker.
Earnings Surprises
| Period | Actual | Estimate | Surprise | Surprise % |
|---|---|---|---|---|
|
Dec 2025 (Q4)
|
$-0.50 | $-0.14 | -0.3613 | -260.49% |
|
Sep 2025 (Q3)
|
$-0.21 | $-0.13 | -0.0825 | -64.71% |
|
Jun 2025 (Q2)
|
$-0.19 | $-0.12 | -0.0727 | -61.98% |
|
Mar 2025 (Q1)
|
$-0.24 | $-0.08 | -0.1584 | -194.12% |
Financial Statements
| Nonoperating Income/Loss | -$48.14K |
| Depreciation and Amortization | $363.09K |
| Research and Development | $16.36M |
| Operating Income/Loss | -$28.71M |
| Income/Loss From Continuing Operations After Tax | -$28.75M |
| Income/Loss From Continuing Operations Before Tax | -$28.75M |
| Net Income/Loss | -$28.75M |
| Net Income/Loss Attributable To Noncontrolling Interest | $0.00 |
| Net Income/Loss Attributable To Parent | -$28.75M |
| Net Income/Loss Available To Common Stockholders, Basic | -$28.75M |
| Participating Securities, Distributed And Undistributed Earnings/Loss, Basic | $0.00 |
| Preferred Stock Dividends And Other Adjustments | $0.00 |
| Basic Earnings Per Share | -$0.98 |
| Diluted Earnings Per Share | -$0.98 |
| Diluted Average Shares | 29,253,292 |
| Assets | $6.84M |
| Current Assets | $332.91K |
| Noncurrent Assets | $6.51M |
| Fixed Assets | $2.49K |
| Other Non-current Assets | $6.50M |
| Liabilities | $11.86M |
| Current Liabilities | $11.76M |
| Accounts Payable | $9.94M |
| Other Current Liabilities | $1.83M |
| Noncurrent Liabilities | $100.00K |
| Equity | -$6.10M |
| Equity Attributable To Noncontrolling Interest | $0.00 |
| Equity Attributable To Parent | -$6.10M |
| Temporary Equity | $1.07M |
| Temporary Equity Attributable To Parent | $1.07M |
| Liabilities And Equity | $6.84M |
| Net Cash Flow From Operating Activities | -$14.24M |
| Net Cash Flow From Operating Activities, Continuing | -$14.24M |
| Net Cash Flow From Investing Activities | -$466.42K |
| Net Cash Flow From Investing Activities, Continuing | -$466.42K |
| Net Cash Flow From Financing Activities | $9.44M |
| Net Cash Flow From Financing Activities, Continuing | $9.44M |
| Net Cash Flow | -$5.26M |
| Net Cash Flow, Continuing | -$5.26M |
| Comprehensive Income/Loss | -$28.75M |
| Comprehensive Income/Loss Attributable To Noncontrolling Interest | $0.00 |
| Comprehensive Income/Loss Attributable To Parent | -$28.75M |
| Other Comprehensive Income/Loss | $0.00 |